News

Military champion has Prytime Medical ready for prime time

Prytime Medical Devices Inc. CEO David Spencer said his company is poised to take its flagship technology ...

Texas Biomed taps new research leadership to help craft aggressive game plan

Joanne Turner has joined Texas Biomedical Research Institute as its new vice president of research. COURTESY ...

Industry Publications

The Mission

The Mission is published by the University of Texas Health Science Center.

UTSA Discovery

UTSA Discovery is published annually for the Office of the Vice President for Research by the Office ...

News
Azaya Therapeutics Inc. to collaborate with the University of Chicago
May 6, 2014

Azaya Therapeutics has formed a research partnership with the University of Chicago to test out a new proprietary formulation of docetaxel.

By W. Scott Bailey, San Antonio Business Journal

Azaya Therapeutics has formed a research partnership with the University of Chicago to test out a new proprietary formulation of docetaxel.

Azaya Therapeutics Inc. has entered into a collaboration with the University of Chicago. Investigators at the university's Ludwig Center for Metastasis Research will work to develop a new application for Azaya's investigational drug ATI-1123.

ATI-1123 is a proprietary formulation of the chemotherapy agent docetaxel, commonly known as Taxotere. The San Antonio-based clinical-stage oncology company is seeking to determine whether a low, clinically safe dose of radiation can significantly enhance the delivery of ATI-1123 to experimental tumors in laboratory mice.

The new study, led by Dr. Stephen J. Kron and Dr. Ralph R. Weichselbaum, will also document the effects of radiation on accumulation of docetaxel in the irradiated tumors, and examine whether the combination leads to greater inhibition of tumor growth.

Azaya officials say the work with University of Chicago researchers may serve as a model for future clinical studies in cancer patients undergoing radiation therapy.

"The outcome of this study could lead to a new treatment option for cancer patients, in which our ATI-1123 liposomal docetaxel would provide a powerful means to improve the benefits of radiotherapy," says Azaya Therapeutics President and CEO Mike Dwyer. "Given the established safety of ATI-1123 on its own, we plan to test this combination in cancer patients if the results of the animal study are promising."

Over half of all cancer patients receive radiotherapy during the course of their disease. Using the radiation to direct liposomal drugs to tumors could improve the benefits of treatment to these patients," Azaya officials say.

 

Stay informed. Subscribe to BioMed SA news alerts.